Study Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) When Administered Via Subcutaneous Auto-injector vs Intramuscular Injection Via Needle and Syringe in Healthy Post-menopausal Women

NCT ID: NCT02937766

Last Updated: 2022-04-21

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE3
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-10-07
• Study Completion Date: 2017-03-27

Brief Summary

To demonstrate that Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) delivered subcutaneously via auto-injector is associated with less pain as compared to intramuscular injections of Makena®

Conditions

Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) in Healthy Post-menopausal Women

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Treatment A

Subcutaneous (SQ) injection using an autoinjector weekly over 4 weeks (4 injections)

Group Type: EXPERIMENTAL

Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)

Intervention Type: DRUG

Treatment B

Intramuscular injection (IM) using syringe and needle weekly over 4 weeks (4 injections)

Group Type: ACTIVE_COMPARATOR

Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)

Intervention Type: DRUG

Interventions

Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)

Intervention Type: DRUG

Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)

Intervention Type: DRUG

Other Intervention Names

Makena SQ; Makena

Eligibility Criteria

Inclusion Criteria

1. Female subjects aged 50 to 75 years of age, inclusive, at Screening Visit.

2. Follicle stimulating hormone (FSH) levels greater than 40 mIU/mL.

3. Naturally or surgically postmenopausal with or without an intact uterus.

Exclusion Criteria

1. Have history of or positive test results for HIV or hepatitis B or C.

2. A significant history or current evidence of chronic infectious disease, organ dysfunction especially cardiovascular, renal, or hepatic disorders or other medical condition.

3. Receiving or have received chronic opioid therapy within 12 months.

4. Unwilling to stop taking/using:

• pain medication.
• topical analgesic or anti-inflammatory treatment. Topical analgesics must be washed out by at least 72 hours in the areas to be treated before randomization.

5. History of alcohol abuse (regularly drinks > 4 units of alcohol per day; 8 oz. beer, 3 oz. wine, 1 oz. spirits) or prescription/illicit drug abuse in the last 12 months.

6. Currently taking any estrogen/progesterone hormone replacement therapy (HRT).

7. History of allergy or sensitivity to hydroxyprogesterone caproate, castor oil or any of the constituents of the study medications or history of any drug hypersensitivity or intolerance.

8. Poorly controlled diabetes (Hgb A1C >8).

9. Current or history of thrombosis or thromboembolic disorders.

10. Known or suspected breast cancer, other hormone-sensitive cancer or tumor, or history of these conditions within the last 5 years.

11. Any current or recent (within previous 12 months) vaginal bleeding.

12. Uncontrolled hypertension.

13. A chronic pain condition (i.e. chronic back pain) that may confound the assessments of injection pain.

• Minimum Eligible Age: 50 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

AMAG Pharmaceuticals, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Neil Singla, MD

Role: PRINCIPAL_INVESTIGATOR

Lotus Clinical Research, LLC

Locations

Lotus Clinical Research, LLC

Pasadena, California, United States

Countries

United States

Other Identifiers

AMAG-HPC-HPM-301

Identifier Type: -

Identifier Source: org_study_id